Ozempic activates hunger neurons to sustain weight loss, PNAS study finds
This digest was compiled by AI from multiple sources — links to the originals are below.
A study published in PNAS overturns the long-held belief that GLP-1 drugs like Ozempic suppress hunger neurons, showing instead that they activate AgRP neurons to promote sustained weight loss. Blocking these neurons significantly weakened the drug's fat-burning effects, confirming their essential role. The discovery reframes the understanding of how semaglutide and Wegovy maintain weight reduction.
The PNAS Study
A new study in Proceedings of the National Academy of Sciences upends the conventional understanding of how weight-loss drugs like Ozempic work. Researchers analyzed long-term semaglutide treatment in mice, focusing on AgRP neurons in the hypothalamus that typically stimulate hunger. Contrary to the belief that these drugs curb appetite by silencing AgRP cells, the team observed sustained activation of these neurons. The activation triggered mitochondrial adaptations and synaptic rewiring via a corticosteroid signaling pathway.
Clinical Implications
When the researchers blocked AgRP neuronal activity, semaglutide’s ability to reduce body weight and burn fat was sharply attenuated. This indicates that the drug’s therapeutic effect depends on turning on hunger neurons rather than turning them off. The brain appears to use this adaptive circuit as a defense against starvation during extended calorie restriction. The findings point toward novel drug targets that could amplify weight loss by selectively engaging this pathway.
What's Next
The scientific community is expected to scrutinize the findings and pursue human studies to validate the mechanism. It remains unclear how quickly these insights might translate into next-generation obesity treatments, given the complexity of neural circuits and potential side effects.
1 source
Ozempic activates hunger neurons to sustain weight loss, PNAS study finds
